Home / Lung Cancer / Clinical Trials / First Line Trials

First Line Trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

     ClinicalTrials.gov Identifier:              NCT04613596    
 
This study is currently recruiting participants.
 
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Alberta
Cross Cancer Institute, Edmonton
Contact: Quincy Chu    780 432-8248     
 
British Columbia
BCCA - Cancer Centre for the Southern Interior, Kelowna
Contact: Sara Kristina Taylor    250 712-3996     

BCCA - Vancouver Cancer Centre, Vancouver
Contact: Daniel John Renouf    604 877-6000 ext 672357
     
Ontario
Kingston Health Sciences Centre, Kingston
Contact: Francisco Vera-Badillo    613 533-6430 ext 79893     

London Regional Cancer Program, London
Contact: Stephen Welch    519 685-8640     

Ottawa Hospital Research Institute, Ottawa
Contact: John Hilton    613 737-7700 ext 75086     

University Health Network, Toronto
Contact: Lillian Siu    416 946-2911
     
Quebec
The Jewish General Hospital, Montreal
Contact: Petr Kavan    514 398-1444
     
Saskatchewan
Allan Blair Cancer Centre, Regina
Contact: Kimberly Hagel    306 766-2691     

Saskatoon Cancer Centre, Saskatoon
Contact: Sunil K. Yadav    306 655-2710
 

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

      ClinicalTrials.gov Identifier:            NCT05094336    
 
This study is currently recruiting participants.
 
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
 
The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors

Alberta
Cross Cancer Institute, Edmonton

Ontario
Princess Margaret Cancer Centre, Toronto
 

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

      ClinicalTrials.gov Identifier:            NCT05241873    
 
This study is currently recruiting participants.
 
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

Ontario
Princess Margaret Cancer Centre

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

      ClinicalTrials.gov Identifier:              NCT04185883      
 
This study is currently recruiting participants.
 
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors

Quebec
Laval
 

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

      ClinicalTrials.gov Identifier:             NCT03093116    

This study is currently active and recruiting participants
 

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.

Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.


Alberta
Edmonton

British Colombia
Vancouver

Ontario
Brampton
Ottawa
Toronto

 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

        ClinicalTrials.gov Identifier:                 NCT04919811   
 

This study is currently recruiting participants.
 

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years

Alberta
Cross Cancer Institute, Edmonton
Contact    855-569-6305     
 
Ontario
Princess Margaret Hospital, Toronto
Contact    855-569-6305   
 

A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001) 

      ClinicalTrials.gov Identifier:              NCT05067283     
 
This study is currently recruiting participants.
 

This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.


Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II)

        ClinicalTrials.gov Identifier:                 NCT04919811   
 

This study is currently recruiting participants.

The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC. 

Ontario
Princess Margaret Cancer Centre, Toronto
 
Quebec
McGill University Health Centre Research Institute, Montréal
 
       ClinicalTrials.gov Identifier:              NCT04619797      

This study is currently recruiting participants. 
 
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

Alberta
Cross Cancer Institute, Edmonton
 
Ontario
Royal Victoria Regional Health Centre, Barrie
Victoria Hospital - London Health Sciences Centre, London
Lakeridge Health, Oshawa
Sault Area Hospital, Sault Ste Marie
Princess Margaret Cancer Centre, Toronto
 
Quebec
Universite de Montreal - Hopital Maisonneuve-Rosemount, Montreal
         ClinicalTrials.gov Identifier:                    NCT03178552         

This study is currently recruiting participants. 

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Alberta
Cross Cancer Institute, Edmonton
 
Ontario
Royal Victoria Regional Health Centre, Barrie
William Osler Health System, Brampton Civic Hospital, Brampton
London Health Sciences Centre · Victoria Hospital, London
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa
Sunnybrook Health Sciences Centre, Toronto
Princess Margaret Hospital, Toronto
 
Quebec
Jewish General Hospital, Montreal
IUCPQ (Hôpital Laval), Quebec
 
Saskatchewan
Saskatoon Cancer Agency, Saskatoon
 
Manitoba
CancerCare Manitoba, Winnipeg
        ClinicalTrials.gov Identifier:                  NCT04380636       
 
This study is currently recruiting participants.

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC.
 
Quebec
Centre Hopitalier de l'Universite de Montreal - CHUM, Montreal
 

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer 

        ClinicalTrials.gov Identifier:                  NCT03991819    

This study is currently recruiting participants.
 
This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.
 
Ontario
Princess Margaret Cancer Centre, Toronto


Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

        ClinicalTrials.gov Identifier:                  NCT03793179    

This study is currently recruiting participants.
 
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.

Alberta
Calgary
Edmonton

British Colombia
Surrey
Vancouver

New Brunswick
Saint John

Ontario
Kingston 
St. Catherines
Thunder Bay
Toronto

Prince Edward Island
Charlottetown

Quebec
Montreal
Quebec City

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS) 

        ClinicalTrials.gov Identifier:                  NCT04966676   
 

This study is currently recruiting participants.
 

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.


Ontario
Princess Margaret Cancer Centre, Toronto
 

Study of Crizotinib for ROS1 and MET Activated Lung Cancer 

      ClinicalTrials.gov Identifier:             NCT04084717      

This study is currently active and recruiting participants
 
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.

Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.

Ontario
Princes Margaret Hospital, Toronto
 

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation 

      ClinicalTrials.gov Identifier:             NCT04449874   

This study is currently active and recruiting participants
 

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.


Ontario
The Ottawa Hospital
Princess Margaret Cancer Centre, Toronto

Quebec
Jewish General Hospital, Montreal
 
      ClinicalTrials.gov Identifier:              NCT05067283     
 
This study is currently recruiting participants.
 

This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.


Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto
 

 

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) 

        ClinicalTrials.gov Identifier:                  NCT04563338    
 
This study is currently recruiting participants.
 

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants.

This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or bevacizumab.


Ontario
Princess Margaret Cancer Centre, Toronto
 

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors 

      ClinicalTrials.gov Identifier:              NCT03645928      
 
This study is currently recruiting participants.
 
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.

Ontario
Toronto

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) 
 

     ClinicalTrials.gov Identifier:              NCT05384626      
 
This study is currently recruiting participants.

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.
 
Phase 1 will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors.
 
Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-655 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors. 
 
Ontario
Princess Margaret Cancer Centre             
Toronto, Ontario, Canada, M5G 0A3
Principal Investigator: Geoffrey Liu, M.D.
 

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC 

 
     ClinicalTrials.gov Identifier:              NCT03769103     
 

This study is currently recruiting participants.

This open-label, multicenter, randomized phase II study will evaluate the usage of osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly diagnosed, treatment naiive EGFR positive lung cancer.
 
British Columbia
BC Cancer, Vancouver Centre, Vancouver
                Contact: Shilo Lefresne, MD    604 877 6000 ext 2673    [email protected]  
                Contact: Cheryl Ho, MD    604 877 6000 ext 2445    [email protected] 
 
Ontario
Princess Margaret Hospital, Toronto       
                Contact: Adrian Sacher        
                Contact: David Shultz        
Sunnybrook Health Sciences Centre, Toronto     
                Contact: Mark Doherty        
                Contact: Arjun Sahgal      

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations 

 
     ClinicalTrials.gov Identifier:              NCT05048797    
 
This study is currently recruiting participants.
 
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
 
British Columbia
Vancouver
 
Ontario
Brampton
Toronto
 
Quebec
Montreal
 

Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients KRAS G12C Mutation KRYSTAL-7
 

     ClinicalTrials.gov Identifier:              NCT04613596    
 
This study is currently recruiting participants.
 
 
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
 
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS <50% and who are candidates for first line treatment.
 
British Columbia
Vancouver
 
Ontario
Ottawa 
Toronto

 

Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7 

      ClinicalTrials.gov Identifier:              NCT04613596     
 
This study is active but not recruiting participants.

This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.


British Columbia
Vancouver

Ontario
Hamilton
Toronto
 

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

 
ClinicalTrials.gov Identifier: NCT03564691
 
This study is active but not recruiting participants.

 
This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.

Ontario
Hamilton
Ottawa
Toronto

A Study of Osimertinib with or without Chemotherapy as 1st Line Treatment in Patients with Mutated Epidermal Growth Factor Receptor NSCLC (FLAURA2)

 
        ClinicalTrials.gov Identifier:                 NCT04035486        

This study is active but not recruiting participants. 
 
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer.

Alberta
Calgary
Edmonton

Ontario
Toronto
 
Quebec
Montreal
 

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrilizumab (MK-3475) with or without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults with Metastatic Nonsquamous NSCLC (MK-7902-006/E7080-G000-315/LEAP-006)

         ClinicalTrials.gov Identifier:                    NCT03829319          

This study is active but not recruiting participants
 
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

Ontario
Juravinski Cancer Centre (Site 0407), Hamilton
Kingston Health Sciences Centre (Site 0414), Kingston
Lakeridge Health (Site 0406), Oshawa
Sault Area Hospital (Site 0413), Sault Ste Marie

Quebec
Hopital Cite de la Sante de Laval (Site 0400), Laval
CIUSSS l'Ouest de l'Ile de Montreal - St-Marys Hospital (Site 0412), Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0408), Trois-Rivieres  
CHU de Quebec - Universite Laval - Hotel Dieu de Quebec (Site 0403), Quebec  

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

           ClinicalTrials.gov Identifier:                    NCT02576574        

This study is active but not currently recruiting.

The purpose of this study is to demonstrate superiority with regard to progression free survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumours.

New Brunswick 
The Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8

Ontario
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
 
        ClinicalTrials.gov Identifier:                  NCT03191786        

This study is active but not currently recruiting. 

This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status of 2-3).
 
New Brunswick
Regional health authority A vitalite health network,   
Moncton, New Brunswick, Canada, E1C 8X3
 
Ontario
Ottawa Hospital Research Institute  
Ottawa, Ontario, Canada, K1Y 4E9
 
Sault Area Hospitals  
Sault Ste Marie, Ontario, Canada, P6A 2C4
 
Princess Margaret Cancer Center  
Toronto, Ontario, Canada, M5G 1Z5
 
Quebec
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology        
Montreal, Quebec, Canada, H3T 1E2
 

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

         ClinicalTrials.gov Identifier:                    NCT03829332          

This study is active but not currently recruiting paricipants. 
 
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
 
Alberta
Cross Cancer Institute (Site 0400)               
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Study Coordinator, 780-432-8762      
 
Ontario
William Osler Health System (Brampton Civic Hospital) (Site 0402)              
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 58389   
  
Windsor Regional Cancer Program (Site 0404)           
Windsor, Ontario, Canada, N8W 2X3
Contact: Study Coordinator, 519-253-5253     
 
         ClinicalTrials.gov Identifier:                    NCT03516981        

This study is active but not currently recruiting paricipants. 

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)              Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      


 
Quebec
Jewish General Hospital (Site 0307)              Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674   
 
          ClinicalTrials.gov Identifier:                   NCT04129502         
 
This study is active but not currently recruiting.
 
The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

British Columbia
BC Cancer Agency, Vancouver

Alberta
Tom Baker Cancer Centre, Calgary

Ontario
William Osler Health System, Brampton
Princess Margaret Hospital, Toronto

Quebec
Hopital du Sacre Coeur de Montreal, Montreal

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

         ClinicalTrials.gov Identifier                  NCT02414139        

This study is active but not currently recruiting participants

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
 
Nova Scotia
Novartis Investigative Site                              
Halifax, Nova Scotia, Canada, B3H 1V7

Ontario
Novartis Investigative Site                               
Ottawa, Ontario, Canada, K1H 8L6
 
         ClinicalTrials.gov Identifier:                 NCT03631199       

This study is active but not curently recruiting. 

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 
Toronto, Ontario, Canada, M5G 1Z6
 
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6

Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

        ClinicalTrials.gov Identifier:                  NCT03052608         

This study is active but not curently recruiting. 

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population.

Ontario
Princess Margaret Cancer Centre                             
Toronto, Ontario, Canada, M5G 2M9

Quebec
McGill University Health Centre                                
Montreal, Quebec, Canada, H4A 3J1
 

A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive NSCLC (LIBRETTO-431)

        ClinicalTrials.gov Identifier:                  NCT04194944      
 
This study is active but not currently recruiting.
 
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Alberta
Cross Cancer Institute

Ontario
Princess Margaret Hospital, Toronto
 

A Study of Novel Anti-cancer Agents in Patients with Previously Untreated NSCLC (MAGELLAN)

 
        ClinicalTrials.gov Identifier:                  NCT03819465     
 
This study is active but not curently recruiting.
 
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Alberta
Edmonton

Ontario
Ottawa
Toronto

A Study of Amivantamab and Lazertinib Combination Therapy vs. Osimertinib in Locally Advanced or Metastatic NSLC (MARIPOSA)

        ClinicalTrials.gov Identifier:                  NCT04487080     

This study is active but not recruiting participants. 
 
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto
Juravinski Cancer Centre, Hamilton

Quebec
McGill University Hospital, Montreal
 

A Study of Combination Amivantamab and Carboplatin-Permetrexed Therapy, Compared with Carboplatin-Permetrexed, in Participants with Advanced or Metastatic NSCLC Characterized by EGFR Exon 20 Insertions (PAPILLON)

        ClinicalTrials.gov Identifier:                  NCT04538664      
 
This study is active but not currently recruiting.
 
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Alberta
Edmonton

Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto

Quebec
McGill Universtiy Health Centre, Montreal
 

Study of Pembrolizumab (MKL-3475) with or without Maintenance Olaparib in Frist-line Metastatic Squamous NSCLC (MK-7339-008/KEYLINK-008)

 
        ClinicalTrials.gov Identifier:                  NCT03976362      
 
This study is active but not currently recruiting.

 
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC.
 

Nova Scotia
Nova Scotia Health Authority (Site 0103), Halifax

Ontario
Juravinski Cancer Centre (Site 0107), Hamilton
Kingston Health Sciences Centre (Site 0102), Kingston
Stronach Regional Cancer Centre (Site 0100), Newmarket

Quebec
CISSS de la Monteregie-Centre (Site 0101), Greenfield Park
Hopital Cite de la Sante de Laval (Site 0105), Laval
CIUSSS Ouest de l'Ile - St Mary's Hospital, Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0106), Trois-Rivieres 
 

An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

        ClinicalTrials.gov Identifier:                  NCT02477826       
 
This study is active but not curently recruiting. 

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC).
The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer.

Alberta
Cross Cancer Institute, Edmonton

Newfoundland and Labrador
St. John’s NL

Ontario
London

Quebec
Montreal
Rimouski
Trois Rivieres

Saskatchewan
Regina
Saskatoon

Trial of BMS-986012 in Combination With Platinum and Etoposide

        ClinicalTrials.gov Identifier:                  NCT02815592      
 
This study is active but not curently recruiting. 
 
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Alberta
Local Institution
Edmonton, T6G 1Z2
Contact: Site 0005   
 
Ontario
Local Institution
Ottawa,  K1H 8L6
Contact: Site 0008   
     
Local Institution
Toronto,  M5G 2M9
Contact: Site 0006    

A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

 
        ClinicalTrials.gov Identifier:                  NCT04026412      
 

This study is active but not currently recruiting.
 
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Ontario
Kingston
London
Oshawa
Windsor

Quebec
CISSS du Bas-Saint Laurent Hopital Regional de Rimouski
Troid-Rivieres
 

Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD)

      ClinicalTrials.gov Identifier:             NCT03485378     

This study is active but not currently recruiting.
   
This is a prospective phase II study of Stereotactic Ablative Radiotherapy (SABR) in patients with Non-Small Cell Lung Cancer (NSCLC) and co-existent Interstitial Lung Disease (ILD), to determine oncologic and toxicity outcomes. Patients will be divided into 3 separate cohorts based on the ILD-GAP index.
 
Ontario
London Regional Cancer Program of the Lawson Health Research Institute
UHN Princess Margaret Cancer Centre
 
Quebec
CHUM Université de Montréal